Neurofilament Light Protein In Blood Predicts Regional Atrophy In Huntington Disease
Eileanoir B. Johnson, MSc, Lauren M. Byrne, MSc, Sarah Gregory, PhD, Filipe B. Rodrigues, MD, Kaj Blennow, MD, PhD, Alexandra Durr, MD, PhD, Blair R. Leavitt, MD, Raymund A. Roos, MD, Henrik Zetterberg, MD, PhD, Sarah J. Tabrizi, MBChB, PhD, Rachael I. Scahill, PhD, and Edward J. Wild, MBChB, PhD, For the TRACK-HD Study Group
Objective Neurofilament light (NfL) protein in blood plasma has been proposed as a prognostic biomarker of neurodegeneration in a number of conditions, including Huntington disease (HD). This study investigates the regional distribution of NfL-associated neural pathology in HD gene expansion carriers.
Methods We examined associations between NfL measured in plasma and regionally specific atrophy in cross-sectional (n = 198) and longitudinal (n = 177) data in HD gene expansion carriers from the international multisite TRACK-HD study. Using voxel-based morphometry, we measured associations between baseline NfL levels and both baseline gray matter and white matter volume; and longitudinal change in gray matter and white matter over the subsequent 3 years in HD gene expansion carriers.
Results After controlling for demographics, associations between increased NfL levels and reduced brain volume were seen in cortical and subcortical gray matter and within the white matter. After also controlling for known predictors of disease progression (age and CAG repeat length), associations were limited to the caudate and putamen. Longitudinally, NfL predicted subsequent occipital gray matter atrophy and widespread white matter reduction, both before and after correction for other predictors of disease progression.
Conclusions These findings highlight the value of NfL as a dynamic marker of brain atrophy and, more generally, provide further evidence of the strong association between plasma NfL level, a candidate blood biomarker, and pathologic neuronal change.
Share this page